Narrow search
Showing 1 - 10 of 36,531
Cover Image
From Randomised Clinical Trials to Clinical Practice: A Pragmatic Cost-Effectiveness Analysis of Paclitaxel in First-Line Therapy for Advanced Ovarian Cancer
Limat, Samuel; Woronoff-Lemsi, Marie-Christine; Menat, … - In: PharmacoEconomics 22 (2004) 10, pp. 633-641
Introduction: Paclitaxel plus cisplatin is considered to be the standard first-line therapy for advanced ovarian cancer … objective of this study was to compare the clinical and economic outcomes associated with paclitaxel-cisplatin (PC) and … out varying unit costs, medical practices and administration of paclitaxel. Results: The incremental cost of the PC …
Persistent link: https://www.econbiz.de/10005590550
Cover Image
Chemotherapy Administration: Modelling the Costs of Alternative Protocols
Haywood, Philip; de Raad, Johan; van Gool, Kees; Haas, … - In: PharmacoEconomics 30 (2012) 12, pp. 1173-1186
Background and Objective:Background and Objective: The increasing cost of chemotherapy is placing greater pressures on limited healthcare budgets. A potentially important, but often overlooked, aspect of chemotherapy is the cost associated with administration. This study aims to develop a better...
Persistent link: https://www.econbiz.de/10010614376
Cover Image
Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK
Brown, Ruth E.; Hutton, John; Burrell, Anita - In: PharmacoEconomics 19 (2001) 11, pp. 1091-1102
Objective: To compare clinical and economic study data for docetaxel, paclitaxel and vinorelbine in the treatment of … adverse effect rates from phase III clinical trial data for docetaxel, paclitaxel and vinorelbine. Costs were taken from UK …, the incremental cost-utility ratio for docetaxel versus paclitaxel was Lstg 1995 per quality-adjusted life year (QALY …
Persistent link: https://www.econbiz.de/10005590325
Cover Image
Docetaxel: A Pharmacoeconomic Review of its Use in the Treatment of Metastatic Breast Cancer
Lamb, Harriet M.; Wiseman, Lynda R. - In: PharmacoEconomics 14 (1998) 4, pp. 447-459
largely palliative. Recent studies with the taxoids docetaxel and paclitaxel suggest that these agents are effective second … and US healthcare systems. All analyses compared docetaxel with paclitaxel. Since no direct clinical comparisons of these … docetaxel ranged from <0.3% less to 13% more than those of paclitaxel. When utilities were evaluated, docetaxel was associated …
Persistent link: https://www.econbiz.de/10005590405
Cover Image
The Measurement of Contingent Valuation for Health Economics
Bayoumi, Ahmed M. - In: PharmacoEconomics 22 (2004) 11, pp. 691-700
In health economics, contingent valuation is a method that elicits an individual Contingent valuation questions can be targeted to any of the following groups: the general population, to value health insurance premiums for programmes; users of a health programme, to value the associated...
Persistent link: https://www.econbiz.de/10005243144
Cover Image
Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework: Some Considerations
McIntosh, Emma - In: PharmacoEconomics 24 (2006) 9, pp. 855-868
A great advantage of the stated preference discrete choice experiment (SPDCE) approach to economic evaluation methodology is its immense flexibility within applied cost-benefit analyses (CBAs). However, while the use of SPDCEs in healthcare has increased markedly in recent years there has been a...
Persistent link: https://www.econbiz.de/10005449123
Cover Image
The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals
Glennie, Judith L.; Torrance, George W.; Baladi, Jean … - In: PharmacoEconomics 15 (1999) 5, pp. 459-468
The first edition of the Guidelines for Economic Evaluation of Pharmaceuticals: Canada was published in November 1994. At that time, the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) was assigned the task of maintaining and regularly updating the Canadian Guidelines....
Persistent link: https://www.econbiz.de/10005449189
Cover Image
Willingness to Pay as a Measure of Health Benefits
Bala, Mohan V.; Mauskopf, Josephine A.; Wood, Lisa L. - In: PharmacoEconomics 15 (1999) 1, pp. 9-18
In this paper, we discuss the use of cost-benefit analysis (CBA) for evaluating new healthcare interventions, present the theoretical basis for the use of willingness to pay as a method for valuing benefits in a CBA and describe how to obtain willingness-to-pay (WTP) measures of health benefits...
Persistent link: https://www.econbiz.de/10005449256
Cover Image
Willingness To Pay: What's in a Name?
Gafni, Amiram - In: PharmacoEconomics 14 (1998) 5, pp. 465-470
Despite renewed enthusiasm for the use of willingness to pay (WTP) in healthcare applications, there are still a lot of objections, resentment and scepticism regarding the desirability and feasibility of this technique. Objections can be classified into different categories: e.g. theoretical,...
Persistent link: https://www.econbiz.de/10005449276
Cover Image
A `League Table' of Contingent Valuation Results for Pharmaceutical Interventions: A Hard Pill to Swallow?
Sach, Tracey H.; Smith, Richard D.; Whynes, David K. - In: PharmacoEconomics 25 (2007) 2, pp. 107-127
Pharmaceutical expenditure represents a large percentage of total healthcare expenditure, and has thus received much attention within the economic evaluation literature. However, although the number of contingent valuation (CV) studies measuring willingness to pay (WTP) in healthcare has...
Persistent link: https://www.econbiz.de/10005404845